Compare Lumen Technologies Inc (LUMN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Merck & Co., Inc. — how do they compare? Lumen Technologies Inc trades at $5.28 (market cap $5.73B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 61.3× Lumen Technologies Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Merck & Co., Inc. for 98 Days on average.
| LUMN | MRK | |
|---|---|---|
Market Cap | $5.73B | $351.28B |
Volume | 17,079,799 | 7,969,665 |
Sector | Media | Health |
52-Week High | $11.83 | $156.43 |
52-Week Low | $5.28 | $82.49 |
Typical Hold Time | 40 Days | 98 Days |
Enterprise Value | $17.35B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lumen Technologies (LUMN) trades at $5.56, down 5.92% with bearish technical signals. The company reported mixed Q2 2026 results, beating EPS estimates but showing negative profitability metrics. Recent strategic moves include transferring to Nasdaq and launching Intelligent Internet services targeting AI-driven enterprise networking. Revenue declined to $12.4B in 2025 with a net loss of $1.74B, though operating cash flow remains strong at $4.74B. Analyst sentiment is cautious with 61% hold ratings.
LUMN presents a high-risk turnaround opportunity with potential from AI networking growth but faces significant challenges including $17.49B debt load, declining legacy revenue, and negative ROE. The stock's deep value (P/S 0.47) attracts speculative interest, but execution risks and competitive pressures warrant caution. Near-term catalysts include Q3 earnings and Nasdaq listing transition.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
